Walleye Capital’s AYTU BioPharma AYTU Stock Holding History

Walleye Capital’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-29,125	Closed	-$108K	–	3177
2022 Q3	$108K	Buy	+29,125	New	+$221K	﹤0.01%	2388

Other funds holding AYTU

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Walleye Capital's AYTU Position: Q4 2022 in Review

Walleye Capital sold out of AYTU BioPharma (AYTU) in Q4 2022, closing a stake of 29,125 shares — an estimated $108K sold.

Walleye Capital first reported a position in AYTU in Q3 2022 and held it in 1 quarter. The position peaked at $108K in Q3 2022. 36 funds tracked by Wall St. Rank hold AYTU as of Q4 2022.

Walleye Capital reported no remaining AYTU BioPharma position as of Q4 2022 after selling out during the quarter.
Walleye Capital sold 29,125 AYTU BioPharma shares in Q4 2022, an estimated $108K.
Walleye Capital first reported a position in AYTU BioPharma in Q3 2022 and held it in 1 quarter.
Walleye Capital's AYTU BioPharma position peaked at $108K in Q3 2022.
36 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.